Tokyo, Feb. 13 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060653) titled 'A Japanese nationwide multi-institutional retrospective survey of the treatments for neuroendocrine liver metastases
(J-NELM study)' on Feb. 12.
Study Type:
Observational
Primary Sponsor:
Institute - Dokkyo Medical University
Condition:
Condition - neuroendocrine liver metastasis
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - The aim of the study is (1) to examine the effect of first line therapy on progonsis of neuroendocrine liver metastasis (NELM), and (2) to clarify prognostic factors for NELM.
Basic objectives2 - Others
Eligibility:
Age-lower limit - 18
years-old
=
Gender - Male and Female
Key inclusion criteria - Patients who received first-line therapy for neuroendocrine liver metastatsis between Jan 1 2012 through March 31 2025.
Key exclusion criteria - Patients who decline the registration of data.
Target Size - 500
Recruitment Status:
Recruitment status - No longer recruiting
Date of protocol fixation - 2025 Year 09 Month 22 Day
Date of IRB - 2025 Year 12 Month 22 Day
Anticipated trial start date - 2025 Year 12 Month 22 Day
Last follow-up date - 2026 Year 06 Month 30 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000069369
Disclaimer: Curated by HT Syndication.
